Clinical-Epidemiological Pattern of Primary Immunodeficiencies in Malaysia 1987-2006: A 20 year experience in Four Malaysian Hospitals

AIM OF STUDY

To determine the clinical and epidemiological characteristics of patients seen with primary immunodeficiencies referred at four Malaysian Hospitals between 1987 to 2007.

METHODS

Patient data were retrospectively obtained from patient records and supplemented by information from a standardized questionnaires taken at the time of diagnosis from 4 participating hospitals. The completed data were transferred to document records kept by the first author. The diagnoses made were based on criteria set by WHO Scientific Committee 1986.

RESULTS

Fifty one (51) patients with completed records satisfied the criteria of primary immunodeficiencies based on WHO Scientific Committee 1986. Predominant Antibody deficiency (40.4%) is the commonest of the class of primary immunodeficiency (based on modified IUIS classification) followed by phagocytic defect (17.3%), combined immunodeficiencies (15.4%) and other cellular immunodeficiencies (11.5%). The commonest clinical presentation is pneumonia (54%) . A positive Family history with a close family relative afflicted was a strong pointer to diagnosis for PID (52.6%) Primary immnodeficiencies are seen in all the major ethnic groups of Malaysia, predominantly among Malays. As observed in other patient registries, diagnostic delay remains the major cause of morbidity and mortality.

CONCLUSION

Primary immunodeficiencies is relative rare but is an emerging disease in Malaysia. Creating awareness of the disease, may reveal more cases within the community. It is sufficient to be a health issue in Malaysia as in other developing countries in the future.

Tumour-associated upregulation of the IL-4 receptor complex

In a previous study we have shown that monoclonal antibody MR6, which we believe recognizes a component of the human IL-4 receptor complex, binds to a wide variety of epithelial tumours. We have now used this reagent to carry out more detailed analysis of tumours of the breast. Our immunohistochemical data indicate that approximately 30% of these tumours show elevated expression of the molecule to which MR6 binds. In addition, three samples of lymphoma were all MR6-positive. Normal breast tissue from the same patients was either negative or weakly positive. Immunoprecipitation and Western blotting analysis with MR6 show that the molecule expressed on tumour cells is indistinguishable from that on normal tissues. It has an apparent molecular weight of 200 kD, but is highly sensitive to proteolysis yielding a molecule of 145 kD. These data raise the possibility that upregulation of the IL-4 receptor complex may be involved in tumourigenesis. In addition, since only a third of tumours are MR6-positive, the antibody may have potential in differential diagnosis.